This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koyanagi, N. Articles by Kitoh, K. Search for Related Content PubMed PubMed Citation Articles by Koyanagi, N. Articles by Kitoh, K.

In Vivo Tumor Growth Inhibition Produced by a Novel Sulfonamide, E7010, against Rodent and Human Tumors

Department of Cancer Research, Tsukuba Research Laboratories, Eisai Co. Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-26 [N. K., T. N., T. W., K. T., Y. F., H. Y., K. K.]; Experimental Cancer Chemotherapy Research Laboratory Incorporation, Toyonaka, Osaka 561 [F. F.]; and Department of Surgery Research Institute for Microbial Diseases, Osaka University, Suita 565 [M. F., T. T.], Japan

The search for compounds active against solid tumors has led us to the discovery of a novel sulfonamide, E7010 (N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide), which inhibits tubulin polymerization. When administered orally, E7010 showed good antitumor activity against various rodent tumors and human tumor xenografts. In tests on mouse tumor, E7010, administered in doses of 25–100 mg/kg daily for 8 days, inhibited the growth of colon 38 carcinoma inoculated s.c. in mice by 60–99%. E7010 was active against s.c. inoculated M5076 fibrosarcoma (75% tumor growth inhibition), s.c. inoculated Lewis lung carcinoma (84% increase in life span), and i.p. inoculated P388 leukemia (118% increase in life span). In a test on rat tumor, E7010 inhibited the growth of SST-2 mammary carcinoma inoculated s.c. in rats by 84%. In tests on s.c. inoculated human tumor xenografts, E7010, when administered orally, showed a broad spectrum of activity. E7010 inhibited the growth of: four kinds of gastric cancer, H-81, H-111, SC-2, and SC-6 by 60–78%; three kinds of colon cancer, H-143, COLO320DM, and WiDr by 58–83%; three kinds of lung cancer, LC-376, LC-6, and LX-1 by 63–82%; and two kinds of breast cancer, H-31 and MX-1 by 79–87%. In studies on drug-resistant P388 leukemia, E7010 was effective against vincristine-resistant P388, cisplatin-resistant P388, and 5-fluorouracil-resistant P388 sublines in mice. Because of its good activity against rodent tumors and human tumor xenografts, E7010 is currently undergoing Phase I clinical trials.

¹ To whom requests for reprints should be addressed.

Received 8/16/93. Accepted 2/ 2/94.

This article has been cited by other articles:

				E. Fox, J. M. Maris, B. C. Widemann, W. Goodspeed, A. Goodwin, M. Kromplewski, M. E. Fouts, D. Medina, S. L. Cohn, A. Krivoshik, et al. A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors Clin. Cancer Res., February 15, 2008; 14(4): 1111 - 1115. [Abstract] [Full Text] [PDF]

				E. Fox, J. M. Maris, B. C. Widemann, K. Meek, A. Goodwin, W. Goodspeed, M. Kromplewski, M. E. Fouts, D. Medina, S. Y. Cho, et al. A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors. Clin. Cancer Res., August 15, 2006; 12(16): 4882 - 4887. [Abstract] [Full Text] [PDF]

				K. R. Hande, A. Hagey, J. Berlin, Y. Cai, K. Meek, H. Kobayashi, A. C. Lockhart, D. Medina, J. Sosman, G. B. Gordon, et al. The Pharmacokinetics and Safety of ABT-751, a Novel, Orally Bioavailable Sulfonamide Antimitotic Agent: Results of a Phase 1 Study. Clin. Cancer Res., May 1, 2006; 12(9): 2834 - 2840. [Abstract] [Full Text] [PDF]

				A. Yokoi, J. Kuromitsu, T. Kawai, T. Nagasu, N. Hata Sugi, K. Yoshimatsu, H. Yoshino, and T. Owa Profiling Novel Sulfonamide Antitumor Agents with Cell-based Phenotypic Screens and Array-based Gene Expression Analysis Mol. Cancer Ther., February 1, 2002; 1(4): 275 - 286. [Abstract] [Full Text] [PDF]